Farxiga vs Mounjaro
Side-by-side cost comparison based on Medicare Part D data
Farxiga
Dapagliflozin
Manufactured by AstraZeneca
Mounjaro
Tirzepatide
Manufactured by Eli Lilly
Farxiga costs 60% less per claim than Mounjaro ($266.00 vs $673.00). A generic version of Farxiga is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Farxiga | Mounjaro |
|---|---|---|
| Avg Cost Per Claim | $266.00 | $673.00 |
| Total Medicare Spending | $3.0B | $2.5B |
| Total Beneficiaries | 1,340,000 | 524,000 |
| Total Claims | 11,240,000 | 3,680,000 |
| Annual Cost/Patient | $2,229.00 | $4,729.00 |
| Year-over-Year Change | +31.5% | +312.4% |
| Generic Available | Yes | No |
| Patent Expiration | Nov 13, 2025 | May 13, 2036 |
| Manufacturer | AstraZeneca | Eli Lilly |
| Condition | Diabetes | Diabetes |
| Generic Name | Dapagliflozin | Tirzepatide |
Farxiga vs Mounjaro: What the Data Shows
Farxiga (Dapagliflozin) and Mounjaro (Tirzepatide) are both used to treat diabetes. Based on Medicare Part D data, Farxiga costs $266.00 per claim, which is 60% less than Mounjaro at $673.00 per claim.
Medicare spent $3.0B on Farxiga and $2.5B on Mounjaro. In terms of patient reach, Farxiga serves more beneficiaries (1,340,000 vs 524,000).
Year-over-year spending changed +31.5% for Farxiga and +312.4% for Mounjaro. Farxiga saw significant spending growth, suggesting increased utilization or price increases. Mounjaro saw significant spending growth, suggesting increased utilization or price increases.
Farxiga has a generic available, while Mounjaro remains brand-only until its patent expires May 13, 2036.
Frequently Asked Questions
Farxiga is cheaper at $266.00 per claim, compared to $673.00 for Mounjaro. That makes Farxiga about 60% less expensive per claim based on Medicare Part D data.
Yes, both Farxiga and Mounjaro are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Farxiga has a generic version (Dapagliflozin) available, which is typically much cheaper. Mounjaro is currently brand-only, with patent expiring May 13, 2036.
Medicare Part D spent $3.0B on Farxiga covering 1,340,000 beneficiaries, and $2.5B on Mounjaro covering 524,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.